GEN Exclusives

More »

GEN News Highlights

Back to Item »

Novartis’ New CML Drug Outperforms Gleevec as First-Line Therapy for Ph+ Disease

Phase III trial found Tasigna resulted in faster and deeper molecular response and better CCyR.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?